Compare VanEck Junior Gold Miners (GDXJ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Mesoblast Limited — how do they compare? VanEck Junior Gold Miners trades at $92.41, while Mesoblast Limited trades at $18.61 (market cap $2.31B). The key difference: Mesoblast Limited is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.
| GDXJ | MESO | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $156.19 | $20.96 |
52-Week Low | $64.22 | $11.35 |
Market Cap | — | $2.31B |
Enterprise Value | — | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ is trading at $92.16, down 6.31% over the past 24 hours amid bearish technical signals. The ETF shows weakness with moving averages indicating strong selling pressure while oscillators remain neutral. Recent news highlights GDXJ's underperformance compared to peers and questions about its small-cap exposure composition.
The outlook remains cautious with technical indicators favoring sellers and fundamental concerns about portfolio composition. Investment opportunities exist for contrarian investors betting on gold miner recovery, but risks include continued underperformance and market volatility. The bearish technical setup suggests near-term pressure may persist.
MESO is trading at $18.61, up 11.17% today, with strong technical momentum as moving averages signal bullish conditions. The company shows promising revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a -144.33% net income margin. Recent milestones include completing patient recruitment for a Phase 3 chronic low back pain trial and securing a $50 million non-dilutive facility.
The outlook is cautiously optimistic given strong analyst support (45% buy ratings) and commercial progress, but significant execution risks remain. Investors face high valuation multiples (P/S 30.52) and substantial cash burn despite reduced operating expenses. The stock's near-term direction will depend on clinical trial outcomes and revenue acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
